128 related articles for article (PubMed ID: 38186218)
1. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T
Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218
[TBL] [Abstract][Full Text] [Related]
2. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
3. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
[TBL] [Abstract][Full Text] [Related]
4. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism.
Saito S; Ando K; Sakamoto S; Xu M; Yamada Y; Rii J; Kanaoka S; Wei J; Zhao X; Pae S; Kanesaka M; Goto Y; Sazuka T; Imamura Y; Reien Y; Hamaguchi-Suzuki N; Saito S; Hirayama Y; Hashimoto H; Kanai Y; Ichikawa T; Anzai N
Cancer Sci; 2024 Apr; ():. PubMed ID: 38655663
[TBL] [Abstract][Full Text] [Related]
5. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1.
Okanishi H; Ohgaki R; Xu M; Endou H; Kanai Y
Cancer Metab; 2022 Nov; 10(1):18. PubMed ID: 36357940
[TBL] [Abstract][Full Text] [Related]
7. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
[TBL] [Abstract][Full Text] [Related]
8. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
[TBL] [Abstract][Full Text] [Related]
9. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.
Yun DW; Lee SA; Park MG; Kim JS; Yu SK; Park MR; Kim SG; Oh JS; Kim CS; Kim HJ; Kim JS; Chun HS; Kanai Y; Endou H; Wempe MF; Kim DK
J Pharmacol Sci; 2014; 124(2):208-17. PubMed ID: 24492461
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W
Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255
[TBL] [Abstract][Full Text] [Related]
11. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells.
Yamaga T; Suehiro J; Wada Y; Sakurai H
Sci Rep; 2022 Jan; 12(1):1021. PubMed ID: 35046465
[TBL] [Abstract][Full Text] [Related]
12. L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells.
Liu YH; Li YL; Shen HT; Chien PJ; Sheu GT; Wang BY; Chang WW
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681614
[TBL] [Abstract][Full Text] [Related]
13. Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.
Okano N; Hana K; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
In Vivo; 2020; 34(5):2595-2606. PubMed ID: 32871789
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.
Higuchi K; Sakamoto S; Ando K; Maimaiti M; Takeshita N; Okunushi K; Reien Y; Imamura Y; Sazuka T; Nakamura K; Matsushima J; Furihata T; Ikehara Y; Ichikawa T; Anzai N
Sci Rep; 2019 Nov; 9(1):16776. PubMed ID: 31748583
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.
Cormerais Y; Pagnuzzi-Boncompagni M; Schrötter S; Giuliano S; Tambutté E; Endou H; Wempe MF; Pagès G; Pouysségur J; Picco V
J Cell Mol Med; 2019 Apr; 23(4):2711-2718. PubMed ID: 30784173
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.
Toyoshima J; Kusuhara H; Wempe MF; Endou H; Sugiyama Y
J Pharm Sci; 2013 Sep; 102(9):3228-38. PubMed ID: 23712732
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.
Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y
J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
19. L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells.
Satou M; Wang J; Nakano-Tateno T; Teramachi M; Suzuki T; Hayashi K; Lamothe S; Hao Y; Kurata H; Sugimoto H; Chik C; Tateno T
Mol Cell Endocrinol; 2020 Sep; 515():110868. PubMed ID: 32579901
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
Otsuki H; Kimura T; Yamaga T; Kosaka T; Suehiro JI; Sakurai H
Prostate; 2017 Feb; 77(2):222-233. PubMed ID: 27696482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
